| Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials TL Yeh, TM Leissing, MI Abboud, CC Thinnes, O Atasoylu, JP Holt-Martyn, ... Chemical science 8 (11), 7651-7668, 2017 | 208 | 2017 |
| Pharmacological targeting of the HIF hydroxylases–a new field in medicine development MC Chan, JP Holt-Martyn, CJ Schofield, PJ Ratcliffe Molecular aspects of medicine 47, 54-75, 2016 | 147 | 2016 |
| Potent and selective triazole-based inhibitors of the hypoxia-inducible factor prolyl-hydroxylases with activity in the murine brain MC Chan, O Atasoylu, E Hodson, A Tumber, IKH Leung, R Chowdhury, ... PLoS One 10 (7), e0132004, 2015 | 69 | 2015 |
| Structural basis of prolyl hydroxylase domain inhibition by molidustat WD Figg Jr, MA McDonough, R Chowdhury, Y Nakashima, Z Zhang, ... ChemMedChem 16 (13), 2082-2088, 2021 | 28 | 2021 |
| Structure‐activity relationship and crystallographic studies on 4‐hydroxypyrimidine HIF prolyl hydroxylase domain inhibitors JP Holt‐Martyn, R Chowdhury, A Tumber, TL Yeh, MI Abboud, K Lippl, ... ChemMedChem 15 (3), 270-273, 2020 | 24 | 2020 |
| A genomic DNA reporter screen identifies squalene synthase inhibitors that act cooperatively with statins to upregulate the low-density lipoprotein receptor AG Kerr, LCS Tam, AB Hale, M Cioroch, G Douglas, S Agkatsev, O Hibbitt, ... Journal of Pharmacology and Experimental Therapeutics 361 (3), 417-428, 2017 | 10 | 2017 |
| Studies on spiro [4.5] decanone prolyl hydroxylase domain inhibitors JP Holt-Martyn, A Tumber, MZ Rahman, K Lippl, W Figg, MA McDonough, ... MedChemComm 10 (4), 500-504, 2019 | 9 | 2019 |
| Inhibition of JMJD6 by 2‐oxoglutarate mimics MS Islam, CC Thinnes, JP Holt‐Martyn, R Chowdhury, MA McDonough, ... ChemMedChem 17 (1), e202100398, 2022 | 6 | 2022 |
| Structure-guided optimisation of N-hydroxythiazole-derived inhibitors of factor inhibiting hypoxia-inducible factor-α TP Corner, RZR Teo, Y Wu, E Salah, Y Nakashima, G Fiorini, A Tumber, ... Chemical Science 14 (43), 12098-12120, 2023 | 5 | 2023 |
| The selective prolyl hydroxylase inhibitor IOX5 stabilizes HIF-1α and compromises development and progression of acute myeloid leukemia H Lawson, JP Holt-Martyn, V Dembitz, Y Kabayama, LM Wang, A Bellani, ... Nature Cancer, 1-22, 2024 | 1 | 2024 |
| Targeting HIF-Hydroxylases Compromises Disease Initiation and Propagation, and Synergises with Current Therapies to Eliminate Cancer Stem Cells in AML H Lawson, J Holt-Martyn, V Dembitz, J Durko, Y Kabayama, L Wang, ... Blood 140 (Supplement 1), 8731-8732, 2022 | 1 | 2022 |
| OC-0098 Developing modulators of tumour hypoxia through inhibition of cellular oxygen consumption N Machado, J Holt-Martyn, G Rodriguez-Berriguete, E Traynor, R Puliyadi, ... Radiotherapy and Oncology 182, S60, 2023 | | 2023 |
| Novel and selective small molecule inhibitors and activators for the prolyl hydroxylase domain enzyme J Holt-Martyn University of Oxford, 2018 | | 2018 |
| The official journal of the European Federation for Medicinal Chemistry rsc. li/medchemcomm JP Holt-Martyn, A Tumber, MZ Rahman, K Lippl, W Figg Jr, ... | | |
